Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-986419 DR Capsule
BMS-986419 DR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A: BMS-986419 DR Capsule - Fasted | EXPERIMENTAL | - |
| Treatment B: BMS-986419 IR Tablet - Fasted | EXPERIMENTAL | - |
| Treatment C: BMS-986419 IR Tablet - Fed | EXPERIMENTAL | - |
| Treatment D: BMS-986419 Crushed IR Tablet - Fed | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986419 DR Capsule | DRUG | Specified dose on specified days |
| BMS-986419 IR Tablet | DRUG | Specified dose on specified days |
Inclusion Criteria: * Healthy male and female participants without clinically significant deviation from normal, as determined by the investigator, in medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations. * Body mass index (BMI) of 18.0 to 32.0 kilogr...
BMS-986419 DR is an investigational small molecule drug developed by Bristol-Myers Squibb Company (ticker: BMY). It is also known as BMS-986419 DR Capsule. The drug is in Phase 1 clinical development, and its intended therapeutic indication has not been disclosed.
BMS-986419 DR is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. Bristol-Myers Squibb is the sponsor of the clinical trial evaluating this drug candidate.
BMS-986419 DR is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this drug candidate.
BMS-986419 DR has been evaluated in one completed Phase 1 trial, NCT05963932, titled "A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants." The trial enrolled 60 healthy adult volunteers in the United States and was randomized and controlled.
Yes, BMS-986419 DR Capsule is an alternative name for BMS-986419 DR. Both names refer to the same investigational small molecule developed by Bristol-Myers Squibb Company. The completed Phase 1 trial NCT05963932 evaluated an immediate-release tablet formulation of BMS-986419.